The possible inhibition of lipid deposition into vascular tissues by a novel angiotensin II type 1 receptor antagonist, olmesartan, was investigated in a primate highcholesterol model. Twelve monkeys that were fed a high-cholesterol (4% cholesterol and 6% corn oil) diet for 6 months were divided into two groups: one group was given olmesartan medoxomil (10 mg/kg per day), and the other group was given no medication. A further control group of six monkeys was fed a normal diet throughout the study. The level of low-density lipoprotein (LDL) cholesterol was increased by the high-cholesterol diet, whereas that of high-density lipoprotein (HDL) cholesterol was decreased. Olmesartan decreased the areas of lipid deposition on the aortic surface and intimal cross-section area, but not the mean blood pressure and the levels of LDL and HDL cholesterol. The
Introduction
It is well known that hyperlipidaemia and hypertension are risk factors for the development of atherosclerosis, but a reduction in lipid level and blood pressure (BP) does not necessarily result in inhibition of the development of atherosclerosis in animal models. [1] [2] [3] [4] [5] Angiotensin II (A II) has been shown to be a potent vasoconstrictor, and it also promotes the growth of vascular smooth muscle cells via the activation of several growth factors. 1 It was previously reported that angiotensin-converting enzyme (ACE) activity in atherosclerotic lesions in monkeys fed a high-cholesterol diet was increased significantly compared with that of a normal-diet group. [3] [4] [5] In this atherosclerotic model, both ACE inhibitor and A II type 1 (AT 1 )-receptor antagonist significantly reduced the progression of atherosclerosis. 5 These compounds did not affect BP and plasma cholesterol level in these normotonic, hypercholesterolaemic animals. Therefore, the A II action may be specifically related to the development of atherosclerosis. The mechanism of A II in the development of atherosclerosis is thought to include various A-II-induced processes such as the induction of growth factors, inflammatory cytokines and adhesion molecules, and the reduction of endo- thelial function via suppression of nitric oxide synthesis. [6] [7] [8] [9] The mechanism of reduction of lipid deposition by AT 1 -receptor antagonist in primates has, however, remained unclear.
To clarify the anti-atherosclerotic mechanism of AT 1 -receptor antagonist in primates, we investigated whether an AT 1 -receptor antagonist, olmesartan, affects endothelial function and serum markers of inflammation and growth factors in monkeys that were fed a high-cholesterol diet.
Methods

Experimental protocol
Monkeys (Macaca fascicularis, n = 18) of both sexes were purchased from Keari Co (Osaka, Japan). The body weight of these monkeys ranged from 4.3 to 6.2 kg. All monkeys were housed at room temperature (23-26°C) with a 12-h light-dark cycle and had free access to food and water. Six monkeys were fed a normal diet for 6 months (normal-diet group). Twelve monkeys, which were fed a high-cholesterol diet for 6 months, were equally divided into a highcholesterol-diet control group and a group that was given olmesartan medoxomil (10 mg/kg/day, orally). The high-cholesterol diet, which contained 4% cholesterol and 6% corn oil, and the normal diet were purchased from Oriental Yeast Co (Osaka).
At baseline and at 1 month, 3 months and 6 months, the systolic BP (SBP) and heart rate were monitored directly using a catheter (Suflo) (Termo, Tokyo, Japan) with a transducer in monkeys under anaesthesia with ketamine hydrochloride (10 mg/kg intramuscularly). Blood samples were taken to measure levels of lipid at baseline and at 2 months, 4 months and 6 months. At the end of the 6-month treatment period, the monkeys were anaesthetized with ketamine hydrochloride (10 mg/kg intramuscularly) and killed by exsanguination. The descending thoracic aortas were quickly removed for histological and biochemical analysis.
Lipid levels in plasma
The levels of total cholesterol, low-density lipoprotein (LDL) cholesterol and high-density lipoprotein (HDL) cholesterol were measured at baseline and at 2 months, 4 months and 6 months using an automatic lipid analyser (7250, Hitachi, Tokyo, Japan).
Histological analysis
The areas of the atherosclerotic lesions of the thoracic aortas were measured. 5 The thoracic aorta was fixed with buffered formalin. The fixed tissue was stained with Oil Red O for visualization of the presence of lipid deposits on the intimal surface. The atherosclerotic area was calculated as the ratio of the Oil-Red-O-stained area to the total surface area with an image analyser (VM-30, Olympus, Tokyo). Immunostaining with antibody to macrophages was used to stain the tissue, employing HAM-56 antibody (DAKO Corporation, Carpinteria, CA, USA).
10
Vascular response
The carotid arteries were removed for experiments on vascular relaxation. The arteries were cut into helical strips, 15 mm long and 2.0 mm wide. The artery strip was placed on a myograph under a resting tension of 2.0 g. The bathing medium was Tyrode's solution (137 mmol/l sodium chloride, 2.7 mmol/l potassium chloride, 1.8 mmol/l calcium chloride, 1.1 mmol/l magnesium chloride, 0.42 mmol/l sodium dihydrogen phosphate, 12 mmol/l sodium bicarbonate and 5.7 mmol/l glucose, pH 7.4). The medium was maintained at 37°C and bubbled continuously with 5% CO 2 in oxygen. After the equilibration period, the artery was contracted with noradrenaline (1 mol/l) and then relaxed with acetylcholine dose-dependently (10 nmol/l to 1 mol/l).
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Serum markers
ELISA kits were used to determine the serum levels of transforming growth factor (TGF)-␤1, macrophage colony-stimulating factor (M-CSF) and intracellular adhesion molecule (ICAM)-1 (R&D Systems, Minneapolis, MI, USA).
Statistical analysis
All results are represented as means ± standard error of the mean. Differences were considered significant at P Ͻ 0.05 with Duncan's multiple range test.
Results
General conditions
All monkeys appeared to be healthy, and there were no differences in body weight, SBP or heart rate among the animals of the normal-diet group and those of high-cholesterol-diet group treated with olmesartan, or untreated, after 1 month, 3 months and 6 months.
Lipid levels in plasma
After 2 months, 4 months and 6 months, the levels of total and LDL cholesterol in the high-cholesteroldiet group were significantly greater than those in the normal-diet group (P Ͻ 0.01), whereas the level of HDL cholesterol in the high-cholesterol-diet group was significantly decreased (Figure 1 ). Olmesartan did not affect the cholesterol levels in the monkeys fed a high-cholesterol diet (Figure 1) . Figure 2 shows segments of the aorta stained with Oil Red O from the three groups of monkeys. Areas of atherosclerotic lesions in thoracic aortas were not observed in the normal-diet group. In the high-cholesterol-diet group, the ratio of the atherosclerotic area to the total area was calculated to be 72 ± 6%, while in the group fed the high-cholesterol diet plus treatment with olmesartan, this ratio was significantly reduced to 25 ± 14% (P Ͻ 0.05 vs high-cholesterol group). Figure 3 shows typical photographs of the aortic cross-sections from the groups that had been fed the normal diet, the high-cholesterol diet and the highcholesterol diet plus treatment with olmesartan. The intimal area and the ratio of intimal area to the medial area in the high-cholesterol-diet group were significantly decreased by olmesartan treatment (P Ͻ 0.05 vs high-cholesterol group) (Figure 4) . Immunostaining with antibody to macrophages was localized in the intimal layer of vessels in the highcholesterol-diet group. In sections from the olmesartan-treated monkeys, however, there were very few positive cells immunostained by antibody to macrophages.
Histological analysis
Vascular response
Acetylcholine (10-1000 nmol/l) caused an endothelium-dependent relaxation in a concentrationresponse manner in all groups. The endotheliumdependent relaxation in the high-cholesterol-diet group was significantly decreased compared with that in the normal-diet group (P Ͻ 0.05). The endothelium-dependent relaxation in monkeys fed a high-cholesterol diet and treated with olmesartan was restored to normal.
Serum markers
Serum TGF-␤1 and ICAM-1 levels were significantly increased in the high-cholesterol-diet group compared with the normal-diet group (P Ͻ 0.05), and the M-CSF level also tended to be increased (P Ͻ 0.05). The M-CSF, TGF-␤1 and ICAM-1 levels in the highcholesterol-diet group were 213%, 140% and 281%, respectively, if these levels in the normal-diet group
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were taken as 100%. The high levels of M-CSF and TGF-␤1 in the high-cholesterol-diet group were reduced by olmesartan treatment, and there were no significant differences in levels compared with the normal-diet group.
Discussion
As previously reported, olmesartan inhibited lipid deposition in the thoracic aorta in monkeys fed a high-cholesterol diet without reduction of BP and serum cholesterol levels. 5, 12 Although high BP is an important risk factor in the development of atherosclerosis, the inhibitory mechanism of lipid depo- sition by olmesartan is not related to BP. In this atherosclerotic monkey model, the plasma levels of total and LDL cholesterol in monkeys fed the highcholesterol diet were significantly increased compared with those in the normal-diet monkeys, whereas the levels of HDL cholesterol were significantly reduced (P Ͻ 0.01). It is well known that LDLcholesterol levels are increased and that HDL-cholesterol levels are reduced in patients with atherosclerosis, suggesting that changes in these cholesterol levels have an important role in the development of atherosclerosis. In fact, the development of atherosclerosis in this model is thought to depend on abnormalities of LDL-and HDL-cholesterol levels. Olmesartan, however, reduced lipid deposition into vessels without changing these cholesterol levels. Therefore, the anti-atherosclerotic effect of olmesartan does not necessarily depend on the reduction of BP and the plasma cholesterol level.
Generally, plasma cholesterol levels have been thought to be a risk marker for the development and progression of atherosclerosis, and, in fact, hypercholesterolaemia induces the development of atherosclerosis in animal models. 3, 5, 12 Recent papers have suggested that cytokines, growth factors and adhesion molecules may relate to the development of the atherosclerosis.
3,13 Levels of pro-inflammatory cytokine, M-CSF, are reported to be upregulated with the development of atherosclerosis. 14, 15 The migration of monocytes into the endothelial layer is induced by M-CSF and this factor increases cholesterol uptake by macrophages, resulting in foam cell formation. 14, 15 In this study, the M-CSF level was increased in monkeys fed a high-cholesterol diet, while there was a trend for reduction to normal levels by treatment with olmesartan, though this was not significant. Angiotensin II is known to induce TGF-␤1, which directly stimulates the synthesis of matrix molecules and blocks matrix degradation, and the reduction of the serum TGF-␤1 level by an AT 1 -receptor antagonist plays an important part in preventing tissue damage. 16, 17 Previously, we reported that the level of TGF-␤1 mRNA in aorta was increased in monkeys fed a high-cholesterol diet but that an ACE inhibitor, imidapril, reduced lipid deposition in vascular tissues with a reduction in the increased TGF-␤1 mRNA level. 3 The intracellular adhesion molecule, ICAM-1, is also induced by A II and plays an important part in mediating the localization of monocytes in the intimal surface. 13, 18 In this study, olmesartan also tended to reduce the levels of both TGF-␤1 and ICAM-1 induced by the high-cholesterol diet, though the reduction was not significant. Therefore, increases in these inflammatory markers may be an important factor in the development of atherosclerosis and for its detection. The inhibition of such increases in these markers by olmesartan may therefore be important in inhibiting the development of atherosclerosis.
The proliferation of the intimal area of atherosclerotic lesions was mainly dependent on the accumulation of macrophages. These findings were also observed in human atherosclerotic lesions. 19, 20 Keidar reported that A II induces modification of LDL to oxidized LDL, which is taken up into macrophages to encourage foam cell formation. 21 Angiotensin II also induces the accumulation of macrophages by the induction of the monocyte chemoattractant protein-1, which is known to induce the activation and migration of monocytes. 22 Moreover, in this study, olmesartan tended to reduce serum M-CSF and ICAM-1 levels, both of which also induce the infiltration of monocytes into the intimal layer and the activation of macrophages, and these actions may also reduce the accumulation of macrophages in the intimal layer. Therefore, reduction in the accumulation of macrophages into the intimal layer by olmesartan may be the predominant mechanism for the suppression of the intimal area.
Endothelial dysfunction has been observed in atherosclerotic lesions in patients and atherosclerotic models. 23, 24 In the intimal layer of atherosclerotic lesions, activated macrophages induce superoxide formation via the activation of 12-or 15-lipoxygenases. 23 It is observed that smooth muscle cells activated by A II also induce NAD(P)H-dependent oxidases, which promote superoxide formation. 7 The increase of superoxide formation in the intimal layer induces endothelial dysfunction via the reduction of nitric oxide synthesis from endothelial cells. 24 In this study, the high-cholesterol diet significantly reduced relaxation induced by acetylcholine, an endothelium-dependent vasodilator, suggesting that the vascular tissues of atherosclerotic lesions show an endothelial dysfunction, which is the first step in the development of atherosclerotic plaque. The acetylcholine-induced relaxation in those monkeys fed a high-cholesterol diet was, howJournal of Human Hypertension ever, significantly improved by olmesartan. The anti-atherosclerotic mode of action of olmesartan may therefore be involved in improvement of endothelial dysfunction.
In conclusion, the anti-atherosclerotic effect observed with olmesartan is brought about by suppression of growth factors, chemokines and adhesion molecules, inhibition of macrophages into the intimal layers, and alleviation of endothelial dysfunction.
